BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nuvation Bio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Nuvation Bio's drugs run\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05303519-10904@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:safusidenib: Phase 3 readout est. (NCT05303519)
DESCRIPTION:safusidenib\, phase 3\, Glioma.\nStudy: SIGMA (Safusidenib in I
 DH1 Mutant Glioma Maintenance)\nEstimated primary completion: 1 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/safusidenib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05303519
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564324-2075@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Taletrectinib: Phase 3 readout est. (NCT06564324)
DESCRIPTION:Taletrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Pos
 itive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients\n
 Estimated primary completion: January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/taletrectinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06564324
URL:https://assetmemo.bio/drug/taletrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07712757-10904@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:safusidenib: Phase 3 readout est. (NCT07712757)
DESCRIPTION:safusidenib\, phase 3\, Glioma.\nStudy: Safety and Efficacy Stu
 dy of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma\nEstimat
 ed primary completion: May 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/safusidenib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07712757
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154706-2075@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Taletrectinib: Phase 3 readout est. (NCT07154706)
DESCRIPTION:Taletrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 hase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Po
 sitive NSCLC (TRUST-IV)\nEstimated primary completion: 30 August 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/taletrectinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07154706
URL:https://assetmemo.bio/drug/taletrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07703436-10904@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:safusidenib: Phase 2 readout est. (NCT07703436)
DESCRIPTION:safusidenib\, phase 2\, Glioma.\nStudy: Safety and Efficacy Stu
 dy of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued
  Vorasidenib Treatment Due to Progressive Disease\nEstimated primary compl
 etion: September 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/safusidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07703436
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
